Cymbalta Withdrawal MDL Again Denied By JPMDL

(October 12, 2015, 9:50 AM EDT) -- WASHINGTON, D.C. — For the second time in 10 months, the Judicial Panel on Multidistrict Litigation (JPMDL) on Oct. 9 denied a plaintiffs’ motion to centralize federal lawsuits alleging withdrawal symptoms from the antidepressant Cymbalta, saying there have been no “significant change in circumstances” since an MDL was first proposed and denied (In Re: Cymbalta [Duloxetine] Products Liability Litigation [No. II], MDL Docket No. 2662, JPMDL).

(Cymbalta MDL order available. Document #28-151015-011R.)

In the most recent petition, two plaintiffs proposed an MDL that would have consisted...
To view the full article, register now.